NFL legend Tom Brady has ignited a firestorm of controversy by revealing his current dog is actually a clone of his deceased pet, raising serious questions about the normalization of biotechnology that many Americans find deeply unsettling.
Celebrity Wealth Enables Controversial Science Experiment
Tom Brady publicly announced in November 2025 that his current dog, Junie, is a genetic clone of his late pit bull mix, Lua, who passed away in December 2023. The former NFL quarterback, who invested in Dallas-based biotech firm Colossal Biosciences, used his financial influence to access cutting-edge cloning technology through a simple blood draw taken from Lua before her death. This revelation exposes how celebrity wealth can bypass natural processes that ordinary families must accept when losing beloved pets.
Brady defended his decision, stating that he loves his animals and they mean the world to his family, and that cloning gives them a “second chance” with their cherished pet. However, critics immediately questioned whether this reflects healthy grieving or an unhealthy rejection of life’s natural cycles. The timing of the revelation, nearly two years after Lua’s death, suggests this was a calculated decision rather than an impulsive emotional response.
Biotech Industry Exploits Grief for Corporate Profit
Colossal Biosciences, the company that performed the cloning, specializes in ambitious biotechnology projects, including efforts to revive extinct species such as the woolly mammoth. The firm’s acquisition of Viagen Pets & Equine positioned it as a leader in the commercial pet cloning industry, which has operated since the early 2000s. Brady’s dual role as both client and investor creates a concerning conflict of interest, raising questions about whether his endorsement is genuine or financially motivated.
Tom Brady reveals his current dog Junie is a clone of his late dog, Lua, who passed away in 2023:
“I love my animals. They mean the world to me and my family. A few years ago, I worked with Colossal Biosciences and leveraged their non-invasive cloning technology through a simple… pic.twitter.com/E5MrqJks35
— Pop Base (@PopBase) November 4, 2025
The company responded to criticism by emphasizing its enthusiasm for continuing to apply cloning science to conservation efforts. This deflection avoids addressing the fundamental ethical concerns about commodifying life and exploiting pet owners’ grief for corporate gain. The biotech industry’s expansion into emotional manipulation represents a troubling departure from legitimate medical research toward profit-driven ventures that many find morally questionable.
Public Outcry Reflects Traditional Values Under Attack
The public response to Brady’s revelation has been overwhelmingly negative, with many Americans expressing discomfort and outrage at what they view as an unnatural interference with God’s design.
Animal welfare advocates have long criticized pet cloning for the risks posed to surrogate animals during the process and the resources diverted from helping existing shelter animals find homes. The backlash reflects deeper concerns about how technological capabilities are increasingly used to avoid accepting life’s natural processes of loss and renewal.
A message for Tom Brady. Go adopt a dog you psychopath. pic.twitter.com/lSgt42vG9N
— Spike Eskin (@SpikeEskin) November 5, 2025
Critics argue that while Brady mourns his pet through expensive biotechnology, millions of healthy animals in shelters face euthanasia due to a lack of adoption. This stark contrast highlights how wealthy elites pursue technological solutions that ignore practical alternatives rooted in traditional values of stewardship and responsibility. The controversy serves as a reminder that just because science can accomplish something doesn’t mean it should, particularly when it conflicts with natural order and community values.
Sources:
Tom Brady sparks outrage after revealing his new pet is a clone of his late dog Lua